ARDX vs. ZLAB, DVAX, PTGX, AVDL, TARO, AKRO, MORF, EWTX, SUPN, and KURA
Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Zai Lab (ZLAB), Dynavax Technologies (DVAX), Protagonist Therapeutics (PTGX), Avadel Pharmaceuticals (AVDL), Taro Pharmaceutical Industries (TARO), Akero Therapeutics (AKRO), Morphic (MORF), Edgewise Therapeutics (EWTX), Supernus Pharmaceuticals (SUPN), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical preparations" industry.
Zai Lab (NASDAQ:ZLAB) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
Ardelyx has a net margin of -53.08% compared to Ardelyx's net margin of -125.46%. Ardelyx's return on equity of -37.07% beat Zai Lab's return on equity.
41.7% of Zai Lab shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 5.5% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Ardelyx received 297 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 67.58% of users gave Ardelyx an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.
Ardelyx has lower revenue, but higher earnings than Zai Lab. Ardelyx is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zai Lab had 6 more articles in the media than Ardelyx. MarketBeat recorded 9 mentions for Zai Lab and 3 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.85 beat Zai Lab's score of -0.10 indicating that Zai Lab is being referred to more favorably in the media.
Zai Lab currently has a consensus price target of $64.22, indicating a potential upside of 303.67%. Ardelyx has a consensus price target of $12.69, indicating a potential upside of 97.62%. Given Ardelyx's higher probable upside, research analysts clearly believe Zai Lab is more favorable than Ardelyx.
Zai Lab has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Summary
Ardelyx beats Zai Lab on 12 of the 19 factors compared between the two stocks.
Get Ardelyx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
